Aligos Therapeutics (NASDAQ:ALGS) Announces Quarterly Earnings Results, Beats Expectations By $0.95 EPS

Aligos Therapeutics (NASDAQ:ALGS) posted its quarterly earnings data on Thursday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.95, FiscalAI reports. The business had revenue of $27.78 million for the quarter, compared to analyst estimates of $24.68 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%.

Aligos Therapeutics Stock Performance

Shares of ALGS stock traded up $0.77 during mid-day trading on Thursday, hitting $5.51. The company’s stock had a trading volume of 293,190 shares, compared to its average volume of 105,386. The stock has a market cap of $34.11 million, a price-to-earnings ratio of -0.63 and a beta of 2.31. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The business has a 50-day moving average price of $5.33 and a 200 day moving average price of $6.43.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds have recently bought and sold shares of ALGS. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics during the 3rd quarter valued at about $99,000. HRT Financial LP purchased a new stake in Aligos Therapeutics in the fourth quarter worth approximately $106,000. DRW Securities LLC bought a new stake in Aligos Therapeutics in the 4th quarter worth approximately $111,000. XTX Topco Ltd purchased a new stake in Aligos Therapeutics during the 2nd quarter valued at $100,000. Finally, Jane Street Group LLC bought a new position in shares of Aligos Therapeutics during the 4th quarter valued at $226,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ALGS. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Lake Street Capital assumed coverage on Aligos Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Finally, Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.